NPR News

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

Patients whose blood cancers have failed to respond to repeated rounds of chemotherapy may be candidates for a new type of gene therapy that could send their cancers into remission for years. But the two approved therapies, with price tags of hundreds of thousands of dollars, have roiled the insurance approval process, leading to delays and, in some cases, denials of coverage, clinicians and analysts say.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

Pages